BioTuesdays

Tag - H.C. Wainwright

PDS Biotechnology Logo
Markets

HCW ups PDS Biotechnology PT to $20 from $8

H.C. Wainwright raised its price target for PDS Biotechnology (NASDAQ:PDSB) to $20 from $8 ahead of additional data being released at the ASCO meeting this weekend. The stock closed at $10.86 on June 1. “We believe that...

June 2, 2021
Asensus-Surgical
Markets

HCW starts Asensus Surgical at buy; PT $4

H.C. Wainwright launched coverage of Asensus Surgical (NYSE American:ASXC) with a “buy” rating and price target of $4. The stock closed at $2.03 on May 25. Asensus, a surgical robotics company, is digitizing laparoscopy...

May 26, 2021
iTeos Logo
Markets

HCW starts iTeos Therapeutics at buy; PT $37

H.C. Wainwright launched coverage of iTeos Therapeutics (NASDAQ:ITOS) with a “buy” rating and $37 price target. The stock finished at $23.03 on May 4. ITeos Therapeutics, which is developing next-generation immuno...

May 5, 2021
SioGene-Therapies
Markets

HCW starts Sio Gene Therapies at buy; PT $8

H.C. Wainwright initiated coverage of Sio Gene Therapies (NASDAQ:SIOX) with a “buy” rating and price target of $8. The stock closed at $2.70 on April 29. Sio is a gene therapy company with significant experience and...

April 30, 2021
Akouos
Markets

HCW starts Akouos at buy; PT $25

H.C. Wainwright launched coverage of Akouos (NASDAQ:AKUS) with a “buy” rating and $25 price target. The stock closed at $15.03 on April 26. Akouos is a precision genetic medicine company focused primarily on the...

April 27, 2021
Adicet-Bio
Markets

HCW starts Adicet Bio at buy; PT $27

H.C. Wainwright launched coverage of Adicet Bio (NASDAQ:ACET) with a “buy” rating and $27 price target. The stock closed at $13.11 on April 22. Adicet is focused on developing allogeneic gamma-delta T-cell therapies for...

April 23, 2021
MiMedx Group
Markets

HCW starts MiMedx at buy; PT $20

H.C. Wainwright launched coverage of MiMedx Group (NASDAQ:MDXG) with a “buy” rating and $20 price target. The stock closed at $8.81 on March 18. MiMedx is a wound care industry leader commercializing placental...

March 19, 2021
Plus Therapeutics Logo
Markets

HCW starts Plus Therapeutics at buy; PT $7

H.C. Wainwright launched coverage of Plus Therapeutics (NASDAQ:PSTV) with a “buy” rating and $7 price target. The stock closed at $3.75 on Feb. 10. Plus is focused on developing novel therapies against brain cancer. The...

February 11, 2021
Ocugen
Markets

HCW ups Ocugen to buy from neutral; PT $4.50

H.C. Wainwright upgraded Ocugen (NASDAQ:OCGN) to “buy” from “neutral” with a price target of $4.50, citing a definitive agreement with Bharat Biotech to co-develop, supply, and commercialize Bharat’s COVID-19 vaccine...

February 4, 2021